Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease

European Journal of Clinical Pharmacology

Volumn 65, Issue 12, 2009, Pages 1245-1251

  Arbouw, Maurits E L ^a,b,c   Movig, Kris L L ^c   Egberts, Toine C G ^a,b   Poels, Petra J E ^d   Van Vugt, Jeroen P P ^c   Wessels, Judith A M ^f   Van Der Straaten, R J H M ^f   Neef, Cees ^e   Guchelaar, Henk Jan ^f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Determinants; Discontinuation; Dopamine agonists; Dopamine receptors; Parkinson's disease; Pharmacogenetics; Pramipexole; Ropinirole

Indexed keywords

AMANTADINE; APOMORPHINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIARRHEA; DIZZINESS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HALLUCINATION; HUMAN; HYPERSEXUALITY; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; BENZOTHIAZOLES; COHORT STUDIES; DOPAMINE AGONISTS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 71349086637     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0708-6     Document Type: Article

References (11)

1. O Rascol DJ Brooks AD Korczyn, et al. 2006 Development of dyskinesias in a 5-year trial of ropinirole and L-dopa Mov Disord 21 1844 1850 10.1002/mds.20988 16958094 (Pubitemid 44848929)
2. ME Arbouw KL Movig HJ Guchelaar, et al. 2008 Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials Eur J Clin Pharmacol 64 1021 1026 10.1007/s00228-008-0518-2 1:CAS:528:DC%2BD1cXht1Sqs7jI 18626634
3. MJ Neville EC Johnstone RT Walton 2004 Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 Hum Mutat 23 540 545 10.1002/humu.20039 1:CAS:528:DC%2BD2cXltFyiurg%3D 15146457 (Pubitemid 38720604)
4. T Arinami M Gao H Hamaguchi M Toru 1997 A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia Hum Mol Genet 6 577 582 10.1093/hmg/6.4.577 1:CAS:528: DyaK2sXisFOku7Y%3D 9097961 (Pubitemid 27142107)
5. M Zappia G Annesi G Nicoletti, et al. 2005 Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study Arch Neurol 62 601 605 10.1001/archneur.62.4.601 15824260 (Pubitemid 40489893)
6. P Muglia U Jain JL Kennedy 2002 A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder Behav Brain Res 130 91 95 10.1016/S0166-4328(01)00438-7 1:CAS:528:DC%2BD38XhsFaksrY%3D 11864723 (Pubitemid 34195325)
7. F Jeanneteau B Funalot J Jankovic, et al. 2006 A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor Proc Natl Acad Sci U S A 103 10753 10758 10.1073/pnas.0508189103 1:CAS:528:DC%2BD28XntFWmsbg%3D 16809426 (Pubitemid 44078048)
8. ME Arbouw JP van Vugt TC Egberts HJ Guchelaar 2007 Pharmacogenetics of antiparkinsonian drug treatment: a systematic review Pharmacogenomics 8 159 176 10.2217/14622416.8.2.159 1:CAS:528:DC%2BD2sXhvF2itLY%3D 17286539 (Pubitemid 46268029)
9. KA Grosset JL Reid DG Grosset 2005 Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 1397 1404 10.1002/mds.20525 16092116 (Pubitemid 43072646)
10. K Lundstrom MP Turpin 1996 Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system Biochem Biophys Res Commun 225 1068 1072 10.1006/bbrc.1996.1296 1:CAS:528:DyaK28Xlt1ajtb0%3D 8780735 (Pubitemid 26319228)
11. J Wang ZL Liu B Chen 2001 Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD Neurology 56 1757 1759 1:CAS:528:DC%2BD3MXltFeitr0%3D 11425949